The Phase 2 program findings of non-steroidal anti-inflammatory drugs (NSAIDs) formulated by Iroko Pharmaceuticals utilizing its partner’s iCeutica’s proprietary SoluMatrix nanotechnology platform, will be presented at the American College of Rheumatology’s annual meeting on 7 November 2011 in Chicago.
Iroko Pharmaceuticals is the sponsor of the Phase 2 program for the development of innovative nano-formulations of the broadly used class of pain drugs. Nano-formulation improves the dissolution of drugs in the body and decreases the particle size of the drugs.
The program’s goal is to reduce the dosage of NSAIDs for the enhancement of their tolerability and safety, while retaining their efficiency. According to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), NSAIDs must be used in minimal dosage for the shortest period regularly with treatment objectives. Iroko Pharmaceuticals has started its Phase 3 program. Iroko develops nano-formulations of NSAIDs as per the advisories of the EMA and the FDA.
Three presentations will be delivered on the results of the Phase 2 program at the American College of Rheumatology’s annual meeting to be conducted at the McCormick Place Convention Center. The titles of the presentations are ‘Acute Pain Relief by a Proprietary, Nano-Formulated Lower-Dose Oral Indomethacin,’ ‘A Phase 2 Study Evaluating the Acute Pain Relief of a Nano-Formulated Oral Naproxen,’ and ‘Application of Nanotechnology to Improve Non-Steroidal Anti-Inflammatory Drugs.’
Source: http://www.iroko.com